AbbVie UK publishes 2018 transparency data; supporting collaboration of medical opinion towards advancing patient care and the development of new medicines

Maidenhead, UK, 28th June 2019 – For the fourth year, AbbVie is pleased to see a rise in the number of doctors willing to consent to their transfers of value being made public.

Each year AbbVie discloses transfers of value to healthcare professionals and healthcare organisations to the Association of the British Pharmaceutical Industry (ABPI).

79 per cent (Nearly 4 in 5) of doctors who received sponsorship, fees or ‘in-kind’ support from AbbVie in 2018 opted-in for their individual data to be made public in the scheme.

AbbVie is encouraged that this marks increased confidence in AbbVie transparency from the medical profession. The collaboration of medical opinion is essential to advance patient care, gain insights into unmet medical needs and progress the development of new medicines. We believe interactions with healthcare professionals, healthcare organisations and patient organisations bring value to patient care.

AbbVie is proud of its collaboration with HCPs and HCOs which has contributed to delivering innovative medicines and has changed the way many diseases impact on patients’ lives. Open communication about these interactions increases understanding of this important collaboration.

Overall the total sum that AbbVie invests in working with and supporting UK healthcare organisations and doctors increased from 2018 compared to the year before with a rise of 31% per cent to £17.1m. Of this figure nearly 58 per cent is on the administration of clinical trials – demonstrating the enduring importance of the UK as a centre of excellence in the development of new medicines.

The full set of AbbVie data is available from the ABPI disclosure UK web portal at: http://www.disclosureuk.org.uk/

Please send data on file requests to UKMediaRelations@abbvie.com.